Lupin on Friday said it has received an establishment inspection report from the United States Food and Drug Administration for its Nagpur facility in Maharashtra. The inspection was conducted between August 5-8, Lupin said. The inspection for the oral solid facility closed without any Form 483 observation, it added. The Nagpur facility is the company’s largest and most advanced oral solid dosage facility and has maintained a solid track record of compliance, Lupin said.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.